drugset / Trial / NCT07258225

Clinical Effectiveness of a Once-daily Regimen of Tigecycline Compared to the Standard Regimen

NCT07258225

Phase 4 Active not recruiting 86 enrolled Air Force Specialized Hospital, Cairo, Egypt
RandomizedParallel-groupSingle-blindTreatment

Summary

To compare the clinical response (efficacy) and the safety of the tigecycline once daily regimen versus the standard regimen (twice daily regimen). Clinical response was categorized as a cure, failure of treatment, or indeterminate outcome.24 Treatment success (Cure): defined as resolution of signs/symptoms of infection, microbiological cure (negative cultures after tigecycline use), improvement of infection markers (leukocytic count, C reactive protein, and procalcitonin). Treatment failure: defined as persistence of signs/symptoms of infection despite antimicrobial therapy, deterioration of infection markers (leukocytic count, C reactive protein, and Procalcitonin). Indeterminate response: subjects who do not have an outcome determination for reasons unrelated to the study drug or infection (e.g., loss to follow-up, withdrawal of consent, etc.) Safety will be assessed by the incidence of adverse events especially which leads to treatment discontinuation.36

Timeline

Start
2024-04-01
Primary completion
2026-02-01
Completion
2026-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tigecycline Small molecule 25 mg
Subject Tigecycline Small molecule 50 mg
Subject Tigecycline Small molecule 100 mg
Subject Tigecycline Small molecule 200 mg

Indications

No indication recorded.